MG0007: An Open-Label Extension Study to Evaluation Rozanolixizumab In Study Participants with Generalized Myasthenia Gravis

Grants and Contracts Details

StatusFinished
Effective start/end date1/26/21 → 3/7/25

Funding

  • Parexel International LLC: $257,518.00